Last reviewed · How we verify
Fremanezumab Prefilled Syringe
Fremanezumab is a monoclonal antibody that blocks calcitonin gene-related peptide (CGRP), a neuropeptide involved in migraine pathogenesis.
Fremanezumab is a monoclonal antibody that blocks calcitonin gene-related peptide (CGRP), a neuropeptide involved in migraine pathogenesis. Used for Episodic migraine prevention, Chronic migraine prevention.
At a glance
| Generic name | Fremanezumab Prefilled Syringe |
|---|---|
| Sponsor | Hospital Clínico Universitario de Valladolid |
| Drug class | CGRP monoclonal antibody |
| Target | CGRP (Calcitonin Gene-Related Peptide) |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | FDA-approved |
Mechanism of action
CGRP is released during migraine attacks and contributes to pain signaling and neuroinflammation. By binding to and neutralizing CGRP, fremanezumab prevents its interaction with CGRP receptors on sensory neurons and blood vessels, thereby reducing migraine frequency and severity. This mechanism has been shown to be effective in both episodic and chronic migraine prevention.
Approved indications
- Episodic migraine prevention
- Chronic migraine prevention
Common side effects
- Injection site reactions
- Nasopharyngitis
- Upper respiratory tract infection
- Headache
Key clinical trials
- Fremanezumab, Migraine and Sleep (PHASE4)
- The FreMRI Study: Advanced MRI on Migraine Patients Treated With Fremanezumab (PHASE4)
- Efficacy of AJOVY (Fremanezumab-vfrm) on Interictal Migraine Related Burden (PHASE4)
- A Study to Test if Fremanezumab Reduces Pain in Patients With Interstitial Cystitis-Bladder Pain Syndrome (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: